JPS5934896A - Preparation of antitumor polysaccharide - Google Patents

Preparation of antitumor polysaccharide

Info

Publication number
JPS5934896A
JPS5934896A JP57145982A JP14598282A JPS5934896A JP S5934896 A JPS5934896 A JP S5934896A JP 57145982 A JP57145982 A JP 57145982A JP 14598282 A JP14598282 A JP 14598282A JP S5934896 A JPS5934896 A JP S5934896A
Authority
JP
Japan
Prior art keywords
culture
polysaccharide
days
medium
cultured
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP57145982A
Other languages
Japanese (ja)
Other versions
JPH0238198B2 (en
Inventor
Yoshiaki Matsuda
松田 義章
Eisuke Mochizuki
英輔 望月
Masaji Nakayama
中山 正次
Toshihiro Omori
俊弘 大森
Nobuo Miyata
信夫 宮田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Snow Brand Milk Products Co Ltd
Original Assignee
Snow Brand Milk Products Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Snow Brand Milk Products Co Ltd filed Critical Snow Brand Milk Products Co Ltd
Priority to JP57145982A priority Critical patent/JPS5934896A/en
Publication of JPS5934896A publication Critical patent/JPS5934896A/en
Publication of JPH0238198B2 publication Critical patent/JPH0238198B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

PURPOSE:To prepare a polysaccharide exhibiting antitumor activity, by culturing a polysaccharide-producing microorganism belonging to Acremonium genus. CONSTITUTION:A microbial strain belonging to Acremonium genus and capable of producing a polysaccharide, e.g. Acremonium sp. SBT7016 (FERM-P No.6601), is cultured on an agar plate medium. The obtained mycelia or conidospores are inoculated in a liquid nutrient medium and cultured at 20-30 deg.C for 3-5 days without agitation or under aeration and then at 25-27 deg.C for 4-6 days under shaking or under aeration and agitation. The objective antitumor polysaccharide is separated from the cultured product.

Description

【発明の詳細な説明】 本発明は、アクレモニウ4@ (Acremonium
)に属する多糖類生産mを培養することにより抗腫瘍活
性を示す多糖類を製造する方法に関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to Acremonium 4@ (Acremonium
The present invention relates to a method for producing polysaccharides exhibiting antitumor activity by culturing polysaccharide-producing m belonging to ).

近年、担子菌類を培養することにより多糖類ヲ活性成分
とする抗腫瘍性物質の製造法が多数報告されており、工
業的に実施されているものもある。
In recent years, many methods for producing antitumor substances using polysaccharides as active ingredients by culturing basidiomycetes have been reported, and some of these methods are being implemented industrially.

一方、不完全菌類のうちには液体培地中で培養すること
によp囲体細胞外に多糖類を生産するものがあることが
報告されているが、有効な抗腫瘍活性を示すものは未だ
知られていない。
On the other hand, it has been reported that some fungi Deuteromycetes produce polysaccharides outside the pepidermal cells when cultured in a liquid medium, but no fungi have yet shown effective antitumor activity. unknown.

本発明者は、土壌中の不完全菌類について有効な抗@瘍
活性を示す多糖類の生産能を有するものについて検討し
た結果、アクレモニウム属(Acremonium)に
属する窮種であるアクレモニウムやスビーシイズ(Ac
remonium sp、 ’) ’Q菌株を培養する
ことにより有効な抗腫瘍活性を示す多糖類を生産するこ
との知見を得て不発明をなすに至った。
As a result of examining fungi Deuteromycetes in soil that have the ability to produce polysaccharides that exhibit effective anti-cancer activity, the present inventor discovered that Acremonium, a rare species belonging to the genus Acremonium, and Subicii ( Ac
They discovered that polysaccharides exhibiting effective anti-tumor activity can be produced by culturing the Q strain, ``remonium sp,'')'', leading to their invention.

因みに、本発明で言う6多糖類”とは異種の糖及び糖以
外の物質が結合したヘテロ多糖類を意味する。
Incidentally, the term "hexapolysaccharide" used in the present invention means a heteropolysaccharide in which different types of sugars and substances other than sugars are bonded.

以下本発明を詳しく説明する〇 本発明は、アクレモニウム属に属する多糖類生産菌を寒
天平板培地で培養して得られる菌糸体又は分生子を液体
培地中で培養し、培養物から抗腫瘍活性を示す多糖類を
採取することを特徴とする。
The present invention will be explained in detail below. The present invention involves culturing mycelia or conidia obtained by culturing polysaccharide-producing bacteria belonging to the genus Acremonium in an agar plate medium in a liquid medium, and obtaining antitumor activity from the culture. It is characterized by collecting polysaccharides exhibiting

本発明で利用するアク、レモニウム属に属する多糖類生
産菌は、土壌(埼玉県秩父市山林土壌)より分離された
ものであって、不完全菌亜門(Deuteromyco
tina)、不完全糸状囲網(Hypho −myce
tθB)のフイアロ型アクレモニクム属(Acremo
nium)に属し、アクレモニウム会スビーシイズ(A
cremonium sp、)日BT 7016の表示
で微工研菌寄第6601号(FBRMP−6601)1
7)番号で工業技術院微生物工業技術研究所に受託され
ている。
The polysaccharide-producing bacterium belonging to the genus Lemonium used in the present invention was isolated from soil (mountain soil, Chichibu City, Saitama Prefecture), and was isolated from the subphylum Deuteromycota.
tina), Hypho-myce
tθB)
belonging to the Acremonium Society (A
cremonium sp,) Japanese BT 7016 display No. 6601 (FBRMP-6601) 1
7) The number has been entrusted to the Institute of Microbial Technology, Agency of Industrial Science and Technology.

なお、Acremonium sp、 SBT 701
6 の同定は、W、  Game、  [Oephal
osporium  −artige  Shim−1
8(1980)及び徳増征二:「防菌防黴Jvol。
In addition, Acremonium sp, SBT 701
6 was identified by W, Game, [Oephal
osporium-artige Shim-1
8 (1980) and Seiji Tokumasu: “Anti-bacterial and anti-mildew Jvol.

8、 No、 2.18 (1980)に準拠して行な
った。
8, No. 2.18 (1980).

以下にAcremoHlum sp、 EIBT 70
16 の菌学的性質を示す。
AcremoHlum sp, EIBT 70 below
16 mycological properties.

(1)生育 麦芽寒天培地上の生育は遅く、コロニーは綿毛状で黄褐
色を呈し、分生子形成により暗褐色となシ、裏面および
寒天は暗褐色になる。表面に褐色水滴を生ずる。ポテト
・デキストロース寒天培地上の生育は速やかであって、
綿毛状で白色を呈し、分生子形成によっても白色であり
、且つ裏面も白色のままである。
(1) Growth Growth on malt agar medium is slow, colonies are fluffy and yellow-brown, dark brown due to conidia formation, and the underside and agar become dark brown. Produces brown water droplets on the surface. Growth on potato dextrose agar medium is rapid;
It is fluff-like and white, and it remains white due to conidia formation, and the back side remains white.

(2ン 形態 ポテト・デキストロース寒天培地におけるスライド培養
についての顕微鏡所見では、菌糸は無色、分生子柄は気
生菌糸側面から直立して生じ無色で隔壁を有しない。分
生子柄はほとんどが無分枝であるが、極く僅かに一度分
枝を含む。
(2) Microscopic findings on slide culture on potato dextrose agar medium show that the hyphae are colorless, and the conidiophores are colorless and do not have septa, growing upright from the side of the aerial hyphae. Although it is a branch, it contains only one branch.

フイアライドは細長で先細りしている。分生子はフイア
ロ型、無色、卵形、単細胞で、粘球となって分生子柄の
先端にかたまる。
The phialides are elongated and tapered. The conidia are phialoid, colorless, ovoid, and unicellular, forming slime balls and clustering at the tip of the conidiophore.

ユクロース、マルトース、ラクトースおよび澱粉を利用
するもキシロースを利用しない。
Utilizes ucrose, maltose, lactose and starch, but does not utilize xylose.

本発明ではAcremonium e2−、 SBT 
7016  f’!ず寒天平板培地で培養して培地表面
に生育したその菌糸体又は分生子或はそれらの混合物を
得る。
In the present invention, Acremonium e2-, SBT
7016 f'! The mycelia or conidia, or a mixture thereof, grown on the surface of the medium are obtained by culturing on an agar plate medium.

この培養は通常20〜30℃、好ましくは25〜27℃
で10〜14日間行なう。また、ここで使用する寒天平
板培地は通常糸状菌、酵母等の培養に用いられるポテト
・デキストロース寒天培地に0.1〜0.3重量係の酵
母エキスを添加し、pHを4〜7に調整したものである
This culture is usually carried out at 20-30°C, preferably at 25-27°C.
Do this for 10 to 14 days. In addition, the agar plate medium used here is a potato dextrose agar medium normally used for culturing filamentous fungi, yeast, etc., with the addition of 0.1 to 0.3 weight percent yeast extract and the pH adjusted to 4 to 7. This is what I did.

次いで、本発明では上述のごとく培養して得ら扛る白色
の菌糸体又は分生子(胞子)或はそtしらの混合物全種
母とし、これを液体培地中で培養する。この液体培地中
での培養に当っては、培養初期(一般には3〜6日間)
には静置培養又は、通気培養で行ない、次いで振とう培
養又は通気攪拌培養を4〜6日間程度行なうことが好ま
しい。このような培養方式を採用するのは、種母として
の菌糸体を液体培養に接種し、静置培養を行なうことな
く、直ちに振とう培養又は通気攪拌培養を行々うときに
は菌糸体の増殖は旺盛となる反面目的物質である多1i
!@を主要成分とする抗帽瘍活性物質の生産が低減する
ことに因る。液体培地中での培養温度は上記2段階の期
間を通して20〜30℃、好ましくは25〜27℃であ
る。
Next, in the present invention, the white mycelium or conidia (spores) obtained by culturing as described above, or a mixture thereof, is used as a whole seed mother, and this is cultured in a liquid medium. When culturing in this liquid medium, the initial stage of culture (generally 3 to 6 days)
It is preferable to perform static culture or aerated culture, followed by shaking culture or aerated agitation culture for about 4 to 6 days. The reason for adopting this culture method is that when the mycelium as a seed mother is inoculated into a liquid culture and immediately subjected to shaking culture or aerated agitation culture without static culture, the mycelium does not grow. On the other hand, poly1i, which is the target substance,
! This is due to a decrease in the production of anti-cancer active substances whose main component is @. The culture temperature in the liquid medium is 20 to 30°C, preferably 25 to 27°C throughout the two stages.

上記液体培養に用いる培地は一般に微生物の培養に適用
される公知の液体培地でよく、例えばグルコースを糖源
とし、ペプトン、#母エキスを含む培地であればよい。
The medium used for the above-mentioned liquid culture may be a known liquid medium that is generally applied to the culture of microorganisms, for example, it may be a medium that uses glucose as a sugar source and contains peptone and #mother extract.

更に、この培地に無機垣頽、アミノ酸、ビタミンあるい
は乳成分等を添加したものも用い得る。
Furthermore, it is also possible to use a medium to which inorganic substances, amino acids, vitamins, milk components, etc. are added.

又、液体培地のpHは4〜7の範囲が適当であシ、滅菌
前のpHが5.5である液体培地の使用が特に好ましい
Further, the pH of the liquid medium is suitably in the range of 4 to 7, and it is particularly preferable to use a liquid medium with a pH of 5.5 before sterilization.

なお、液体培地中での培養は継代的に行なうことが可能
であるが、継代回数の増加に伴って多糖類の生産性が次
第に低下するので液体培地のみによる菌の植えつぎは3
〜5回以内にすべきであるが、多糖体の生産性の観点か
らすれば、寒天平板培地上に生育させた菌糸体全種母と
して新たに液体培養することが有利である。
Although culture in a liquid medium can be carried out successively, the productivity of polysaccharides gradually decreases as the number of passages increases, so it is recommended to inoculate bacteria only in a liquid medium for 3 to 3 days.
However, from the viewpoint of polysaccharide productivity, it is advantageous to perform a new liquid culture using whole mycelia grown on an agar plate medium.

しかし、培養規模が大きくなると(例えば10を以上の
液体培養を行う場合)上記寒天平板培養の菌糸体全種母
として用いることは操作上困難となるので菌培養として
の液体培地での静置培養により得られる培養物を種母と
して用いるとよい。又、寒天平板培養物からの第1伏目
の振とう又は通気攪拌培養物を滅菌生理食塩水で3〜5
倍稀釈し、ホモジナイズしたもの?、種母と用いること
もできる。
However, when the culture scale becomes large (for example, when carrying out liquid culture of 10 cells or more), it becomes operationally difficult to use the entire mycelium as a seed mother for the agar plate culture, so static culture in a liquid medium is used as fungal culture. It is preferable to use the resulting culture as a seed mother. Alternatively, shake or aerate the first bound culture from the agar plate culture for 3 to 5 minutes with sterile physiological saline.
Double diluted and homogenized? , can also be used with seeds.

本発明で利用するAaremonium ep、 5B
T7016の菌糸体(又鉱分生子)を上述のようにして
液体培養すると高粘性物質を生産して培養物自体が高粘
性を示すようになる。この高粘性培養物から目的とする
抗腫瘍活性を有する多糖類を採取するには、抽出手法を
適用し得るが、培養物そのままでは粘性が高い故に抽出
効率がよくないので、培養物を2〜3倍の蒸留水で希釈
し、ミキサーでよく攪拌混合し、この混合物に遠心分離
、ろ過等の手法を施して水溶液画分を得る。また、上記
分別によシ得られる残渣(菌糸体)を蒸留水で2〜3回
洗浄し、再び加水後、例えばワーリングブレンダーで菌
糸体を破砕し、遠心分離して得られる水溶液画分を用い
ることもでき、更に該両分全上記水溶液画分と一緒にし
てもよい。更に又菌糸体の懸濁液そのままの状態でも用
いることが可能である。
Aaremonium ep, 5B used in the present invention
When T7016 mycelia (or mineral conidia) are cultured in liquid as described above, a highly viscous substance is produced and the culture itself becomes highly viscous. Extraction techniques can be applied to collect the desired polysaccharide with antitumor activity from this highly viscous culture, but the extraction efficiency is not good if the culture is used as it is because of its high viscosity. Dilute with 3 times as much distilled water, mix thoroughly with a mixer, and apply techniques such as centrifugation and filtration to this mixture to obtain an aqueous solution fraction. In addition, the residue (mycelium) obtained by the above fractionation is washed with distilled water two to three times, and after adding water again, the mycelium is crushed with, for example, a Waring blender, and the aqueous solution fraction obtained by centrifugation is used. Furthermore, both fractions may be combined with the aqueous solution fraction. Furthermore, it is also possible to use the mycelial suspension as it is.

次いで、これらの水溶液画分中の遊離蛋白、遊離核酸、
還元a!などの夾雑物を除去するために、該両分を活性
炭、弱塩基性イオン交換樹脂又はクロマトグラフィーで
処理する。これらの処理により上記画分の脱色、低分子
物質の除去も行われる。
Next, free proteins, free nucleic acids, and
Reduction a! In order to remove impurities such as, both components are treated with activated carbon, a weakly basic ion exchange resin, or chromatography. These treatments also decolorize the fraction and remove low-molecular substances.

さらに、硫安による頃析、低級アルコールやアセトンを
用いる沈殿法、分子篩、限外濾過等の処理を単独或は組
合わせて適用してもよく、その他培養物からの多糖類の
抽出に用いられるセパグ法や酵素法なども適用し得る。
Furthermore, treatments such as precipitation with ammonium sulfate, precipitation using lower alcohols or acetone, molecular sieves, and ultrafiltration may be applied alone or in combination, and other treatments such as sepag, which is used for extracting polysaccharides from cultures, may be applied. method or enzyme method can also be applied.

上述のごとくして培養物から採取した多糖類は蒸留水に
対する透析を行ない、必要に応じて濃縮した後、凍結乾
燥して製品とする。
The polysaccharide collected from the culture as described above is subjected to dialysis against distilled water, concentrated if necessary, and then freeze-dried to obtain a product.

次に、このようにして得られた多糖類(以下本物質と称
す)の物性について説明する。
Next, the physical properties of the polysaccharide thus obtained (hereinafter referred to as the present substance) will be explained.

外観・・・・・・白色を呈し、加熱すると分解して炭化
する。
Appearance: White in color and decomposes and carbonizes when heated.

融点・・・・・・本物質は明確な融点を示さない。Melting point: This substance does not show a clear melting point.

赤外吸収スペクトル・・・・・・KBr錠剤法により測
定した結果添付図に示すとおりである。
Infrared absorption spectrum: The results measured by the KBr tablet method are as shown in the attached figure.

溶解性・・・・・・水及びジメチルスルホキザイドに可
溶性であるが、一般有機溶剤並びに有機酸には不溶。
Solubility: Soluble in water and dimethyl sulfoxide, but insoluble in general organic solvents and organic acids.

なお、本物質の水溶液は半透膜を通過 せず、2〜10%水溶液のpHは6.2〜6.4であり
、0.1係水溶液の紫外部吸収は認められない。
Note that an aqueous solution of this substance does not pass through a semipermeable membrane, a 2-10% aqueous solution has a pH of 6.2-6.4, and a 0.1% aqueous solution exhibits no ultraviolet absorption.

呈色反応・・・・・・モーリッシュ反応、アンスロン反
応及びニンヒドリン反応は陽性であり、エルソンモルガ
ン反応、バハアル反応及びヨードデンプン反応は陰性で
ある。
Color reaction: Molisch reaction, Anthrone reaction, and ninhydrin reaction are positive, and Elson-Morgan reaction, Bahaal reaction, and iodostarch reaction are negative.

本物質は種々の条件下で薄層クロマトグラフィーを行な
っても原点は移動しない。本物質を2〜4N硫酸で加水
分解し、中和後トリメチルシリル化を行ったものについ
てガスクロマトグラフィーで分析した結果、グルコース
と少量のマンノース及びガラクトースを検出した。また
、本物質を4N塩酸で14時間加水分解した試料につい
てアミノ酸自動分析創で分析した結果ガラクトサミンと
少量のグルコサミン全検出した。
The origin of this substance does not shift even when thin layer chromatography is performed under various conditions. This substance was hydrolyzed with 2-4N sulfuric acid, neutralized, and then trimethylsilylated and analyzed by gas chromatography. As a result, glucose and small amounts of mannose and galactose were detected. In addition, as a result of analyzing a sample obtained by hydrolyzing this substance with 4N hydrochloric acid for 14 hours using an automatic amino acid analysis method, galactosamine and a small amount of glucosamine were all detected.

更に、本物質を水で50#v150rnlの懸濁液とな
し、超音波のような処理を施して十分に可溶化させた後
遠心分離して得られる上清についてゲルろ過或はイオン
交換系のカラムクロマトグラフィーもしくは溶液のpH
調整による溶解度の差を利用した分別手法等を用いて分
析した結果、グルコースを主要な構成成分とする中性糖
およびガラクトサミンを主要構成成分とするアミノ糖の
各重合体と蛋白とから成っていた。
Furthermore, this substance was made into a suspension of 50#v150rnl in water, treated with ultrasonic waves to sufficiently solubilize it, centrifuged, and the resulting supernatant was subjected to gel filtration or ion exchange system. Column chromatography or solution pH
As a result of analysis using a fractionation method that takes advantage of the difference in solubility due to adjustment, it was found that it is composed of polymers of neutral sugars whose main constituent is glucose, amino sugars whose main constituent is galactosamine, and proteins. .

なお、これら成分の含量比率は本物Wk得るための培養
条件や培養物の抽出条件により異なるが、一般には下記
のとおpである。
The content ratio of these components varies depending on the culture conditions for obtaining the authentic Wk and the extraction conditions of the culture, but is generally as follows.

中性糖・・・50〜60亜量チ(フェノール硫酸法咥よ
る全ヘキソースとして) アミノ糖・°・25〜35亜量チ(インドール塩酸法に
よるヘキソサミンとして) 蛋白・・・5〜15京量%(ローリ−フォーリン法によ
る蛋白として) 次に、本発明により得られる多糖類の薬理学的特性につ
いて説明する。
Neutral sugars: 50 to 60 subunits (as total hexose by phenol-sulfuric acid method) Amino sugars: 25 to 35 subunits (as hexosamines by indole-hydrochloric acid method) Proteins: 5 to 15 quintillion units % (as protein by the Lowry-Folin method) Next, the pharmacological properties of the polysaccharide obtained by the present invention will be explained.

(1)急性毒性 マウスは工OR−JOL系、4〜5週令、体重20〜2
5fのものを、ラットはウィスター系、4〜5週令、体
重110〜140 yのもの全それぞれ用いて、各試験
群25匹に対し本物賀ヲ経口並びに腹腔内投与してその
急性毒性試験全下記により行なった。
(1) Acutely toxic mice are OR-JOL strain, 4-5 weeks old, body weight 20-2
5f rats were all Wistar strain, 4 to 5 weeks old, and weighed 110 to 140 y, and were administered orally or intraperitoneally to 25 rats in each test group for all acute toxicity tests. This was done as follows.

本物質を投与後、1週間にわたって各試験動物の一般的
症状、体重変化及び死亡例につき観察した後層殺剖検し
た。結果は下記表のとおりであってLD5Q値が極めて
高いことがわかる。
After administration of this substance, each test animal was observed for one week for general symptoms, changes in body weight, and deaths, followed by necropsy. The results are shown in the table below, and it can be seen that the LD5Q value is extremely high.

(2)抗1111瘍活性 本物質の抗腫瘍活性の検定はSarcoma 180固
型唾瘍を皮下接種したマウス、及びFihrlish腫
瘍細胞を腹腔内に移植したマウスにおけるin viv
o試験法で行なった。
(2) Anti-1111 tumor activity The anti-tumor activity of this substance was assayed in vivo in mice subcutaneously inoculated with Sarcoma 180 solid saliva and in mice intraperitoneally implanted with Fihrlish tumor cells.
It was conducted using the o test method.

(イl  Sarcoma 180固型腫瘍に対する抗
腫瘍活性: 試験動物は工0R−JOL、 6週令雌マウス(体重2
52±31)を採用し、Sarcoma 180腫瘍細
胞はマウスの腹腔内に腹水型で1週間毎に継代している
ものを用いた。試験に当っては接種後−週間口の腹水中
の細胞を取り出し、約400万個を含有する生理食頃水
0 、1 d k試験マウスの右脇腹下部皮下に移植し
た。移植して24時間後に本物質を生理食塩水に50〜
/10ゴの濃度になるように溶解し、120℃15分間
滅菌した溶液i0.25rnlマウスの腹腔内に投与し
、以後10日間連続して投与を行なった。
Antitumor activity against Sarcoma 180 solid tumor: Test animals were 6-week-old female mice (body weight 2
Sarcoma 180 tumor cells were subcultured intraperitoneally in mice in the ascites form every week. For the test, cells from the ascites in the mouth were removed one week after inoculation and subcutaneously transplanted into the lower right flank of saline test mice containing approximately 4 million cells. 24 hours after transplantation, add this substance to physiological saline for 50~
The solution was dissolved to a concentration of 0.25ml/ml and sterilized at 120°C for 15 minutes, and then administered intraperitoneally to 0.25rnl mice, followed by continuous administration for 10 days.

対照マウスには滅菌生理食頃水を0.25rnt同様に
投与した。
Control mice were similarly administered 0.25 rnt of sterile saline water.

1瘍移植後30日経過してマウスを解剖し、増殖した固
型llj!瘍を摘出してその重量を測定することで対照
群との比較を行なった。尚マウスは10匹を1群とした
30 days after transplantation of one tumor, the mouse was dissected and solid llj! A comparison with a control group was made by removing the tumor and measuring its weight. Each group consisted of 10 mice.

その結果、本物質は腫瘍抑制率87.鏝の強い抗腫瘍活
性を示し治療群io匹中6匹のl11瘍は完全に消失し
ていた。
As a result, this substance has a tumor suppression rate of 87. The trowel showed strong antitumor activity, and the l11 tumors in 6 of the io animals in the treatment group had completely disappeared.

ここにおいてSarcoma 180固型・i@瘍に対
する;圃潟抑制率は次式を用いて算出した値である。
Here, the field lagoon suppression rate for Sarcoma 180 solid/i@tumor is a value calculated using the following formula.

0B Csエ 対照群の平均腫瘍重量 TB:  試験群の 本物質のSarcoma 180固型腫瘍に対する有効
な投与量は1日当り5〜15■/神(体重)であって、
常法によI)iR剤化して適用し得る。
0B CsE Average tumor weight TB of control group: The effective dose of this substance for Sarcoma 180 solid tumor in the test group is 5 to 15 cm/cm (body weight) per day,
It can be applied by converting it into an iR agent by a conventional method.

(口l  Fihrliθh腹水唾瘍に対する抗腫瘍活
性:試験動物は工0R−JOL、  8週令雌マウス(
体重252±3F)を採用し、このマウス11匹を1群
とする4群の各々K I X 106個のEhrlis
hl111瘍細胞を移植し、24時間後対照群以外の各
3群に本物質を25η/梅(体重)7日、10り/ k
y (体重)7日並びに2.5η/紛(体重)/8宛そ
れぞれ10日間腹腔内投与して各群の延命効果及び治癒
効果を観察もた。なお、対照群には生理的食塩水のみを
投与した。
(Anti-tumor activity against ascites saliva: Test animals were 8-week-old female mice (
Four groups each consisting of 11 mice (body weight 252±3F) were administered with K I x 106 Ehrlis mice each.
hl111 tumor cells were transplanted, and 24 hours later, this substance was administered to each of three groups other than the control group at 25η/ume (body weight) for 7 days and 10 ri/k.
y (body weight) 7 days and 2.5η/mm (body weight)/8 for 10 days, respectively, to observe the survival effect and healing effect in each group. In addition, only physiological saline was administered to the control group.

結果に下記のとおシであった。The results were as follows.

25      >200    11匹ウニ0匹10
      >200    11匹ウニ0匹2.5 
      >200    11匹中 9匹(註) 1)延命率は下記にょυ算出した。
25 >200 11 sea urchins 0 sea urchins 10
>200 11 sea urchins 0 sea urchins 2.5
>200 9 out of 11 animals (Note) 1) The survival rate was calculated as follows.

2)治癒バ数り各群における腫瘍細胞を移植後60日を
経過して生存しておp且っ腹水の貯留が認められないも
のの数を示す。
2) Number of cured tumors The number of tumor cells in each group that survived 60 days after transplantation and showed no accumulation of ascites is shown.

なお、本発明によシ得られる物質はSarcoma18
0腹水帽瘍に対しても上記と同様な抗腫瘍活性を示した
The substance obtained according to the present invention is Sarcoma18.
It also showed the same antitumor activity as above against 0.0 ascites ulcer.

以下に実施例を示して本発明を更に具体的に説明する。EXAMPLES The present invention will be explained in more detail with reference to Examples below.

実施例1 培地組成: ポリペプトン    1.Of 酵母エキス     5.02 グルコース     30 f 水          1t pH=5.5 の比率から成る液体培地を200−ずつ500d容の三
角フラスコ50本に分注し、綿栓を附した後に120℃
で15分間滅菌し、別に0.3%酵母エキスを添加した
ポテトデキストロース寒天培地で斜面培養しておいたA
cremonium sp、 SBT 7016 f上
記液体培地に接種し、23〜27℃で3日間静置培養を
行なった。ひきつづいてこれ全23〜27℃で5日間、
180 rpmにて回転式の振とう培養を行い、高粘性
の培餐物10tを得た。これに10tの熱水を加えて、
ミキサーで攪拌混合した後to、ooo yにて20分
間遠心分離を行い菌糸体を除去し、粘稠な透明液を得た
。この液の中に予め濃塩酸処理後充分水洗し次いでエタ
ノール、アセトンで洗って乾燥した活性炭−七ライト(
1:1)混合物を重量比で4%加え、室温で16時間攪
拌した。
Example 1 Medium composition: Polypeptone 1. Of yeast extract 5.02 f glucose 30 f water 1 t pH = 5.5 A liquid medium consisting of the following ratio was dispensed into 50 Erlenmeyer flasks with a capacity of 500 d each, and after attaching cotton stoppers, the liquid medium was heated at 120°C.
A.
cremonium sp, SBT 7016 f was inoculated into the above liquid medium, and statically cultured at 23 to 27°C for 3 days. This was continued for a total of 5 days at 23-27℃.
Rotary shaking culture was performed at 180 rpm to obtain 10 tons of highly viscous culture. Add 10 tons of hot water to this,
After stirring and mixing with a mixer, the mixture was centrifuged for 20 minutes using TO, OOO Y to remove mycelium and obtain a viscous transparent liquid. Into this solution was activated carbon-7lite (7L), which had been treated with concentrated hydrochloric acid, thoroughly washed with water, then washed with ethanol and acetone, and dried.
1:1) mixture was added in an amount of 4% by weight, and the mixture was stirred at room temperature for 16 hours.

濾過によシ活性炭−セライト混合物を除去して得られた
液を蒸留水に対して5℃で48時間透析した後、凍結乾
燥したところ灰白色の粉末27.5 Fを得た。このよ
うにして得られた物質はグルコースを主成分とする中性
糖並びにガラクトサミンを主成分とするアミン糖の各重
合体と蛋白から成る多糖類で、その抗腫瘍効果を検定し
た結果、l0R−JOL、  6週令マウスにおける腹
腔内投与ft101’f/kfでのSarcoma 1
80固型腫瘍に対する抑制率は87.3係であった。
The activated carbon-celite mixture was removed by filtration, and the resulting solution was dialyzed against distilled water at 5° C. for 48 hours, and then freeze-dried to obtain an off-white powder of 27.5 F. The substance obtained in this way is a polysaccharide consisting of polymers of neutral sugars whose main component is glucose and amine sugars whose main component is galactosamine, and proteins.As a result of testing for its antitumor effect, it was found that JOL, Sarcoma 1 at ft101'f/kf intraperitoneally administered in 6 week old mice
The inhibition rate against 80 solid tumors was 87.3.

実施例2 培地組成: ポリペプトン     5y 酵母エキス     32 グルコース    302 〜リン酸lカリウム   0.52 リン酸2カリウム   0.5f 塩化マグネシウム   0.32 塩化マンガン   0.05f 水         1t pH=5.5 の比率から成る液体培地を100dずつ500m容三角
フラスコに分注し、綿栓を附した後に120℃で15分
間滅菌したものに、別に寒天斜面培地で培養しておいた
Acremonium sp、 8BT 7016 f
常法によシ接種し、25℃で4日間静置培養した。
Example 2 Medium composition: Polypeptone 5y Yeast extract 32 Glucose 302 - Potassium phosphate 0.52 Dipotassium phosphate 0.5f Magnesium chloride 0.32 Manganese chloride 0.05f Water 1t A liquid consisting of the following ratios: pH=5.5 Dispense 100 d of culture medium into 500 m Erlenmeyer flasks, attach cotton plugs and sterilize at 120°C for 15 minutes, and add Acremonium sp, 8BT 7016 f, which had been separately cultured on an agar slant.
The cells were inoculated in a conventional manner and cultured stationary at 25°C for 4 days.

一方、20を容ジャーファーメンタ−に前記の組成の液
体培地10tf入れ、120℃で30分間滅菌、冷却し
、これに上記の培養物をワーリングプレンダーで均質化
した後移植して、25℃にて2日間静置培養の後、つづ
いて通気ii0.4vvm、攪拌数25Orpmの条件
下で5日間通気攪拌培養を行なった。
On the other hand, put 10 tf of a liquid medium of the above composition into a jar fermenter, sterilize it at 120°C for 30 minutes, cool it, homogenize the above culture with a Waring blender, transplant it, and raise the temperature to 25°C. After static culture for 2 days, aeration agitation culture was performed for 5 days under conditions of aeration II of 0.4 vvm and agitation number of 25 rpm.

得られた培養物を2倍に稀釈し、F布を用いて菌糸体を
分離除去した。
The obtained culture was diluted twice, and the mycelium was separated and removed using F cloth.

このようにして得た透明な粘稠液に容蓋比で10チのア
ンバーライ) XAD −2を加え、室温で2時間混合
攪拌した。上記アンバーライト樹脂を分離後、上溝液に
エタノールを等を添加して、生じる白色沈殿を真空乾燥
したところ、暗灰色の粉末24.52を得た。この粉末
はグルコースを主成分とする中性糖並びにガラクトサミ
ンを主成分とするアミン糖の各重合体と蛋白とから成る
多糖類でその抗腫瘍活性を検定した結果、IOR−JO
L、6週令マウスにおける腹腔的投与量10q/mKよ
シSarecoma 180固型Ill瘍に対する抑制
率は8315チであった・
To the thus obtained transparent viscous liquid was added 10 g of Amberly XAD-2 (container/cap ratio), and the mixture was mixed and stirred at room temperature for 2 hours. After separating the Amberlite resin, ethanol and the like were added to the supernatant liquid, and the resulting white precipitate was vacuum-dried to obtain a dark gray powder 24.52. This powder is a polysaccharide composed of polymers of neutral sugars whose main component is glucose and amine sugars whose main component is galactosamine, and as a result of testing its antitumor activity, the IOR-JO
L. The inhibition rate against Sarecoma 180 solid Ill tumor was 8315 cm after intraperitoneal administration of 10q/mK in 6-week-old mice.

【図面の簡単な説明】[Brief explanation of the drawing]

添附図は本発明によシ得られる多糖類から成る抗腫瘍性
物質のKBr錠剤法により測定した赤外吸収スペクトル
を例示したものである。
The attached diagram illustrates an infrared absorption spectrum measured by the KBr tablet method of an antitumor substance composed of a polysaccharide obtained according to the present invention.

Claims (2)

【特許請求の範囲】[Claims] (1) アクレモニウム属(Acremonium)に
楓する多糖類生産菌を寒天平板培地で培養して得られる
菌糸体又は分生子或はそれらの混合物を液体培地中で培
養し、培養物から抗腫瘍活性を示す多糖類を採取するこ
とを特徴とする抗腫瘍性多糖類の製造法。
(1) Mycelia or conidia or a mixture thereof obtained by culturing polysaccharide-producing bacteria belonging to the genus Acremonium in an agar plate medium are cultured in a liquid medium, and the antitumor activity is determined from the culture. 1. A method for producing an antitumor polysaccharide, which comprises collecting a polysaccharide exhibiting the following.
(2)液体培地中での培養は、20乃至30℃で3乃至
5日間静置又は通気培養し、次いで25乃至27℃で4
〜6日間振とり培養又は通気攪拌培養することによシ行
なう特許請求の範囲第1項記載の製造法。
(2) For culture in a liquid medium, culture at 20 to 30°C for 3 to 5 days, followed by 4 days at 25 to 27°C.
The manufacturing method according to claim 1, which is carried out by shaking culture or aerated stirring culture for 6 days.
JP57145982A 1982-08-23 1982-08-23 Preparation of antitumor polysaccharide Granted JPS5934896A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP57145982A JPS5934896A (en) 1982-08-23 1982-08-23 Preparation of antitumor polysaccharide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57145982A JPS5934896A (en) 1982-08-23 1982-08-23 Preparation of antitumor polysaccharide

Publications (2)

Publication Number Publication Date
JPS5934896A true JPS5934896A (en) 1984-02-25
JPH0238198B2 JPH0238198B2 (en) 1990-08-29

Family

ID=15397450

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57145982A Granted JPS5934896A (en) 1982-08-23 1982-08-23 Preparation of antitumor polysaccharide

Country Status (1)

Country Link
JP (1) JPS5934896A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04109843U (en) * 1991-03-01 1992-09-24 ブラザー工業株式会社 Guideway protection device for processing machines
KR100398065B1 (en) * 1999-12-21 2003-09-19 한국생명공학연구원 A new fungal strain Acremoniem sp. MT70646(KCTC 8973P), novel compounds produced by this strain and their use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04109843U (en) * 1991-03-01 1992-09-24 ブラザー工業株式会社 Guideway protection device for processing machines
KR100398065B1 (en) * 1999-12-21 2003-09-19 한국생명공학연구원 A new fungal strain Acremoniem sp. MT70646(KCTC 8973P), novel compounds produced by this strain and their use

Also Published As

Publication number Publication date
JPH0238198B2 (en) 1990-08-29

Similar Documents

Publication Publication Date Title
Okami Marine microorganisms as a source of bioactive agents
JPS6215560B2 (en)
CN114196564B (en) Tetragenococcus halophilus and application thereof in production of anti-cancer extracellular polysaccharide
GB1564020A (en) Method of producting a polysaccharide through fermentation and the product obtained thereby
EP0067000B1 (en) Production of a nitrogen-containing polysaccharide having antitumour activity
JPS5934896A (en) Preparation of antitumor polysaccharide
JPS58318B2 (en) Method for producing anticancer substances
EP0084334B1 (en) Polysaccharide substance, process for the production of same, pharmaceutical compositions containing the same and their use as medicaments
EP0939082A1 (en) Protein polysaccharide 0041
EP0084333B1 (en) Polysaccharide substance, process for the production of same, pharmaceutical compositions containing the same and their use as medicaments
JP3107455B2 (en) New antibiotic MI481-42F4-A and method for producing the same
EP0304400B1 (en) Phenanthridine derivatives, process for their preparation and medium for performing the process
KR890002256B1 (en) Process for preparing anticanser tf-2
EP0053800B1 (en) Heteroglycan, process for the production of same, and immunological activator containing same
JP2592468B2 (en) Benanomycins A and B, novel antibiotics and their production
JP2594085B2 (en) SF2575, a new antitumor antibiotic, and method for producing the same
JPS61101501A (en) Carcinostatic polysaccharide and its production
JPS62238298A (en) Novel anthracycline antibiotic substance dcp-1 and 2
JPS5998087A (en) Nargenicin c1
JPS6311341B2 (en)
EP0024206A2 (en) Antitumor substance, composition comprising it and process for preparing said substance
HU181104B (en) Process for producing 41 200 rp material of immunity-developing activity
JPH0370719B2 (en)
JPS6210517B2 (en)
JPH04278095A (en) Polysaccharide a-1845, production thereof and microorganism producing the same